TENX NASDAQ
Tenax Therapeutics, Inc.
1W: +5.5%
1M: -7.0%
3M: -88.4%
YTD: -84.4%
1Y: -76.7%
3Y: -92.7%
5Y: -99.9%
$1.72
+0.08 (+4.88%)
Pre-Market: $1.73 (+0.01, +0.87%)
Weekly Expected Move ±12.3%
$1
$2
$2
$2
$2
Credit Risk of going bust: not rated Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
Not rated: no debt. Altman Z'' 6.52.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.00
Neutral
0 bullish
1 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (36)
Tenax Therapeutics, Inc. (NASDAQ:TENX) Stock Has Average Target Price of $14.00 According to Brokerages
Insider Buying: Tenax Therapeutics (NASDAQ:TENX) Director Buys $101,760.00 in Stock
Brokerages Set Tenax Therapeutics, Inc. (NASDAQ:TENX) Price Target at $14.00
Bank of New York Mellon Corp Purchases New Holdings in Tenax Therapeutics, Inc. $TENX
Tenax finds benefit in sicker patient subgroup after Phase 3 trial miss
Tenax plummets on phase 3 failure of pulmonary hypertension drug
Tenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF
Tenax Therapeutics, Inc. (NASDAQ:TENX) Receives Consensus Rating of “Moderate Buy” from Brokerages
Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Wall Street Analysts Predict a 121.36% Upside in Tenax Therapeutics (TENX): Here's What You Should Know
Tenax Therapeutics, Inc. (NASDAQ:TENX) Receives $38.00 Average Price Target from Brokerages
Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Earnings Scheduled For May 12, 2026
Tenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial Officer
Tenax Therapeutics (NASDAQ:TENX) Shares Pass Above 200 Day Moving Average – Here’s What Happened
Tenax Therapeutics appoints Thomas Staab as chief financial officer
Tenax Therapeutics names new CFO
Tenax Therapeutics, Inc. (NASDAQ:TENX) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Tenax Therapeutics (NASDAQ:TENX) Stock Price Crosses Above 200-Day Moving Average – What’s Next?
Tenax Therapeutics (NASDAQ:TENX) Stock Price Passes Above Two Hundred Day Moving Average – What’s Next?
Tenax wins bullish view at Cantor ahead of pivotal readout
This Ingredion Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Boothbay Fund Management LLC Purchases Shares of 352,206 Tenax Therapeutics, Inc. $TENX
What is Lifesci Capital’s Forecast for TENX Q1 Earnings?
Tenax Therapeutics, Inc. (NASDAQ:TENX) Receives $22.50 Average PT from Brokerages
Tenax Therapeutics GAAP EPS of -$0.38 beats by $0.03
Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Tenax Therapeutics (NASDAQ:TENX) Shares Cross Above 200 Day Moving Average – Here’s What Happened
Tenax Therapeutics to Participate in the 2026 Leerink Partners Global Healthcare Conference
Tenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026
Tenax Therapeutics: A Speculative Buy
Tenax Therapeutics: How Lower Variance In Phase 3 Has "Loaded The Dice" For An Asymmetric Repricing
Tenax Therapeutics (NASDAQ:TENX) Stock Crosses Above 200 Day Moving Average – What’s Next?
Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment
Tenax Therapeutics to Participate in Upcoming Investor Conferences